

FOR IMMEDIATE RELEASE

**HealthShares™, Inc., Announces Liquidation
of HealthShares Exchange-Traded Funds**

NEW YORK (November 26, 2008) – The Board of Directors (the “Board”) of HealthShares™, Inc. (the “Company”), a registered investment company, today announced that it has determined to liquidate the Company’s four underlying investment portfolios (the “Funds”) effective December 31, 2008 and subsequently dissolve the Company. The Funds offer shares known as HealthShares™ (the “Shares”) that are listed on NYSE Arca, Inc. (“NYSE Arca”).

The Board’s decision was taken after consultation with XShares Advisors LLC (“XShares”), the investment advisor to the Funds. The Board also carefully considered current market conditions, the inability of the Funds to attract significant market interest since their inception, their future viability as well as their prospects for growth in the Funds’ assets in the foreseeable future, and thereafter determined that it was advisable and in the best interests of the Funds and their shareholders to liquidate the Funds.

“We continue to believe in the fundamentals of the healthcare industry. Unfortunately under these tough market conditions, the Funds were unable to achieve meaningful investor traction,” said Joseph L. Schocken, Chairman and Chief Executive Officer of XShares Group, Inc., parent company of XShares. “We remain strongly committed to bringing our products now under review to market. In 2009, we expect to launch additional products related to the environment and infrastructure.”

December 23, 2008, will be the last day of trading for the Shares on NYSE Arca, and the last day on which creation unit aggregations of the Shares may be purchased or redeemed. The four Funds, and their ticker symbols, are as follows:

- HealthShares™ Cancer Exchange-Traded Fund (HHK)
- HealthShares™ European Drugs Exchange-Traded Fund (HRJ)
- HealthShares™ Diagnostics Exchange-Traded Fund (HHD)
- HealthShares™ Drug Discovery Tools Exchange-Traded Fund (HHV)

NYSE Arca will halt trading in the Shares of the Funds before the open of trading on December 24, 2008, and the Funds will be closed to new investment on that date. Shareholders may sell their Shares on or prior to December 23, 2008. From December 24, 2008 through December 31, 2008, shareholders may be able to sell their Shares to certain broker-dealers who may determine to continue to purchase such Shares, but there can be no assurance that any broker-dealer will be willing to purchase such Shares or that there will be a market for the Shares of the Funds. All sales of Shares to a broker-dealer, whether before or after December 23, 2008, will be subject to typical transaction fees and charges. All shareholders remaining on December 31, 2008 will receive cash equal to the amount of the net asset value of their Shares as of December 31, 2008, which will include any capital gains and dividends into the cash portion of their brokerage accounts. Fund shareholders remaining

on December 31, 2008 will not incur transaction fees to sell their Shares. Other costs of closing the Funds will be borne by XShares.

Effective immediately, the Funds will be in the process of liquidating their portfolios. As a result, each Fund will no longer pursue its investment objective of seeking to track the performance of its respective underlying index. Transaction costs incurred by each Fund in liquidating its portfolio will be included in the calculation of the Fund's net asset value.

For additional information about the liquidation, shareholders of the Funds may call XShares at 1-800-925-2870.

About XShares Advisors LLC

XShares Advisors LLC, a registered investment advisor, sponsors and develops innovative exchange traded products (ETPs). XShares Advisors partners with major institutions and index providers to create and license distinctive intellectual property for its ETPs. For more information, visit the company's website at: www.xsharesadvisors.com.

An investor should carefully consider a Fund's investment objective, risks, charges and expenses before investing. For this and more complete information about the Funds call 800.925.2870 or visit the website www.xsharesadvisors.com/healthshares for a prospectus. Please read the prospectus carefully before investing.

There are risks involved with investing in exchange-traded funds, including possible loss of money. The Funds are not actively managed and are subject to risks similar to stocks, including those related to short selling and margin maintenance. The Funds are subject to increased risks associated with investing in a specific sector compared to a more diversified investment. The prospectus is not an offer to buy or sell the portfolio shares, nor are the Funds soliciting an offer to buy their shares in any jurisdiction where the offer or sale is not permitted.

HealthShares ETFs face additional risks attributable to their investments in small- and medium-capitalization companies which are subject to higher volatility than larger, more established companies. In addition, they are invested in a limited number of securities and a decline in the value of these investments would cause the fund's overall value to decline to a greater degree than in a less concentrated portfolio. HealthShares are subject to additional risks associated with the healthcare and biotechnology sector (i.e., government regulation, patent regulation, etc.). Certain HealthShares ETFs invest in foreign securities that will be subject to certain risks not associated with domestic securities, such as currency fluctuations and changes in political and economic conditions.

XShares Advisors LLC and ALPS Distributors, Inc. are unaffiliated entities.

Distributed by ALPS Distributors, Inc.
HSI 580 Exp. 5/31/09

Contact:

John McInerney

Makovsky + Co.

(212) 508-9628

jmcinerney@makovsky.com